Mezigdomide Clinical Trials
10 recruitingDrug
Phase 19Phase 25
Showing 1–10 of 10 trials
Recruiting
Phase 1
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital25 enrolled3 locationsNCT07032714
Recruiting
Phase 1
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Multiple Myeloma
City of Hope Medical Center15 enrolled1 locationNCT06048250
Recruiting
Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company147 enrolled19 locationsNCT06121843
Recruiting
Phase 1
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Multiple Myeloma
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT07105059
Recruiting
Phase 1Phase 2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Celgene62 enrolled22 locationsNCT06988488
Recruiting
Phase 1
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Abdullah Khan27 enrolled1 locationNCT05981209
Recruiting
Phase 1Phase 2
A Study of Revumenib and Mezigdomide in People With Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
Memorial Sloan Kettering Cancer Center52 enrolled10 locationsNCT07356154
Recruiting
Phase 2
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Refractory Multiple MyelomaRecurrent Multiple MyelomaExtramedullary Disease in Multiple Myeloma
Roswell Park Cancer Institute28 enrolled1 locationNCT06627751
Recruiting
Phase 1Phase 2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Multiple Myeloma
Karyopharm Therapeutics Inc300 enrolled25 locationsNCT02343042
Recruiting
Phase 1Phase 2
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH75 enrolled7 locationsNCT06645678